Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today provided additional data from the company’s ongoing Phase 1/2a SCiStar study designed to evaluate the safety and potential efficacy of AST-OPC1 in the treatment of severe cervical spinal cord injury.

As quoted in the press release:

“We are pleased to provide this update regarding our ongoing clinical trial of AST-OPC1 for the treatment of severe cervical spinal cord injuries in patients for whom there are no viable treatment options and a high unmet medical need,” stated Michael Mulroy, President and Chief Executive Officer.

Click here to read the full press release.